| Microbiome |
1 |
1 |
| Biologic Therapy |
0 |
0.87 |
| Clostridium Difficile Infection |
0 |
0.81 |
| Fecal Transplant |
0 |
0.66 |
| Cancer |
0 |
0.57 |
| Tumor |
0 |
0.38 |
| Toxicology |
0 |
0.33 |
| Skin Cancer |
0 |
0.27 |
| Breast Cancer |
0 |
0.26 |
| COVID-19 |
0 |
0.24 |
| Advanced and Metastatic Breast Cancer |
0 |
0.23 |
| Bacteria |
0 |
0.19 |
| Clinical Guidelines |
0 |
0.17 |
| Clinical Research |
0 |
0.13 |
| Colitis |
0 |
0.13 |
| Food and Drug Administration (FDA) |
0 |
0.13 |
| Immunotherapy |
0 |
0.13 |
| Manipulation |
0 |
0.13 |
| Texas |
0 |
0.13 |
| Antibiotics |
0 |
0.11 |
| Inflammatory Bowel Disease |
0 |
0.11 |
| Ulcerative Colitis |
0 |
0.1 |
| Hepatic Encephalopathy |
0 |
0.09 |
| Autism |
0 |
0.06 |
| Biomedical Technology |
0 |
0.06 |
| Board Certification |
0 |
0.06 |
| Breast |
0 |
0.06 |
| Crohn Disease |
0 |
0.06 |
| Diet |
0 |
0.06 |
| Dietary Fiber |
0 |
0.06 |
| Diversity |
0 |
0.06 |
| Encephalopathy |
0 |
0.06 |
| Europe |
0 |
0.06 |
| Pandemic |
0 |
0.06 |
| Polymerase Chain Reaction |
0 |
0.06 |
| Quality Control (QC) |
0 |
0.06 |
| Refractory |
0 |
0.06 |
| Severe Acute Respiratory Syndrome |
0 |
0.06 |
| Transplantation |
0 |
0.06 |
| Acute Respiratory Distress Syndrome |
0 |
0.04 |
| Bowel Preparation |
0 |
0.04 |
| Hepatitis B Virus |
0 |
0.04 |
| Melanoma |
0 |
0.04 |
| Multiple Sclerosis |
0 |
0.04 |
| Social Determinants of Health |
0 |
0.04 |